Skip to main content
Fig. 2 | Clinical Hypertension

Fig. 2

From: A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

Fig. 2

Flow diagram., FMS/ALD + RSV group, fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg treatment, study group; FMS/ALD group, fimasartan 60 mg/amlodipine 10 mg treatment, control 1 group; FMS + RSV group, fimasartan 60 mg + rosuvastatin 20 mg treatment, control 2 group, FAS, full analysis set; PPS, per protocol set; SS, safety set

Back to article page

Clinical Hypertension

ISSN: 2056-5909

Contact us